Dr. Craig Reeder
Add to your Care-Team
Dr. Craig Reeder
Dr. Craig Reeder
I specialize in
Internal Medicine - Hematology
I have been in practice
My answers and insights have
Helped 40 people
Received 1 doctor agrees
Here are kind words from others
This Thanksgiving, I wanted to share my appreciation for all that you do! Thank you, doctor! :)
I was educated and trained at
Medical / Graduate School
Southern Illinois University School of Medicine
Illinois Wesleyan University
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.
Leukemia., Aug (2012)
Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
Leuk. Res., Sep;36(9):1147-51 (2012)
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
Blood., May;119(21):4860-7 (2012)
Histologic remission of cardiac amyloidosis: a case report.
Amyloid., Jun;19(2):106-9 (2012)
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.
Blood., May;119(19):4391-4 (2012)
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Br. J. Haematol., Feb;156(3):326-33 (2012)
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
Br. J. Haematol., Aug;154(4):477-81 (2011)
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
Am. J. Hematol., Aug;86(8):640-5 (2011)
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
Ann. Oncol., Jul;22(7):1622-7 (2011)
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.
Leukemia., Feb;25(2):341-7 (2011)
Novel therapeutic agents for B-cell lymphoma: developing rational combinations.
Blood., Feb;117(5):1453-62 (2011)
Diagnosis and management of WaldenstrÃ¶m macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
Mayo Clin. Proc., Sep;85(9):824-33 (2010)
Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
Blood., Apr;115(16):3416-7 (2010)
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.
Am. J. Hematol., May;85(5):320-4 (2010)
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
Blood., Feb;115(7):1343-50 (2010)
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
Mayo Clin. Proc., Dec;84(12):1095-110 (2009)
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
Blood., Jul;114(3):518-21 (2009)
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group.
Leuk. Lymphoma., Jun;49(6):1074-80 (2008)
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.
Mayo Clin. Proc., Mar;82(3):323-41 (2007)
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.
Leukemia., Mar;21(3):529-34 (2007)
Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide.
Leuk. Res., Sep;31(9):1185-9 (2007)
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
Mayo Clin. Proc., Aug;81(8):1047-53 (2006)
CD5+ persistent polyclonal B-cell lymphocytosis in a male.
Leuk. Lymphoma., May;33(5-6):593-6 (1999)
Long-term results of laparoscopic splenectomy for immune thrombocytopenic purpura.
Mayo Clin. Proc., Jan;74(1):37-9 (1999)
Dr. Craig Reeder M